Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive HLADQA1*05 Genotyping for the Use of Infliximab in Chinese Crohn's Disease：A Multicenter, Prospective, Controlled, Randomized Study

NCT05813860 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.

NCT NCT05813860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05813860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive HLADQA1*05 Genotyping for the Use of Infliximab in Chinese Crohn's Disease：A Multicenter, Prospective, Controlled, Randomized Study
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 30, 2023
Completion date
October 31, 2026
Enrollment
976 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, infliximab